August 11, 2014 -- Press Release
W. Tim Miller, President and CEO
Frontier Scientific, Inc.
(801) 588-0455 ext. 306
FOR IMMEDIATE RELEASE August 11, 2014
AGRICULTURAL SCIENCE MAKES ORGANIC CONNECTION
FRONTIER SCIENTIFIC ACQUIRES PREMIER AG INDUSTRY SUPPLIER
Logan, Utah – Frontier Scientific, Inc. (FSI) announces the expansion of its agricultural products offering through the acquisition of a leading supplier of insect products to provide researchers proven quality solutions for insecticide compound screening, seed development and crop protection.
Agricultural expansion is a natural fit for FSI’s established areas of expertise in complex supply issues, custom chemistry capabilities, existing che mical offering, compound management for screening, and crop protection pipeline.
“This allows us to expand and strengthen current relationships and provide a solid foundation for future discovery, development and commercialization,” said W. Tim Miller, President and CEO of FSI. “This is a unique way to complement our current applications by leveraging our existing capabilities,” said Miller.
According to a report published by Transparency Market Research, the global crop protection market will grow to $71.8 billion in 2018.
“As the market grows, the need for testing against problem insects will grow. Our core competency is the consistent scaled production and delivery of insect products, principally Lepidopteran species, of agricultural interest,” stated Dave Davis, Senior Director of Operations for this new business unit of FSI.
Existing agricultural projects within FSI include novel compounds in development and field testing to address citrus greening disease, methyl erythritol phosphate pathway inhibitors as herbicides, and light activated compounds being evaluated as fungicides to address crop problems like wheat rust and fusarium wilt in bananas and as insecticides against mosquito larvae and cherry fruit flies.
With this acquisition, FSI will also be expanding its existing protein expression capabilities using insect larvae as the expression host.
The business will operate as Frontier Agricultural Sciences (FSIAG) – www.fsiag.com-- in Newark, DE, at a specialized facility with state-of-the-art insect propagation, packaging and production technology, an operation and team which has shown market-proven consistency for 12 years.
About Frontier Scientific, Inc.: Frontier Scientific, Inc., is a recognized developer and manufacturer of boronic acids, trifluoroborates, catalysts, porphyrin, and small molecule drug discovery compounds and provides custom compound synthesis. Frontier Scientific Services, Inc., a compound logistics and scientific personnel in-sourcing division of FSI, provides solutions for sample management and other common issues when conducting research -- compound library curation, standardization and re-formatting, procurement, storage and distribution, and analytical services. Echelon Biosciences Inc. is the molecular biology division of FSI.
April 17, 2014 -- Press Release
A NATURAL STEP FOR PEPTIDE RESEARCH
Echelon Biosciences acquires California Peptide Research
Salt Lake City - Echelon Biosciences, Inc. (EBI) announces the acquisition of California Peptide Research, Inc. (CPRI) to offer its line of biochemicals and research peptides, and to further drive innovations in the growing peptide research and development markets.
The primary customers of EBI include pharmaceutical and research and development companies, whose research indicates dramatic growth in the peptide therapeutics market and vast expansion over the next five years.
"The acquisition represents a natural, strategic step for Echelon," said W. Tim Miller, President and CEO of EBI.
According to a report published Mar. 13, 2013 by Transparency Market Research, "...the global peptide therapeutics market was valued at USD 14.1 billion in 2011 and is estimated to reach a market worth USD 25.4 billion in 2018..."
"Peptide therapeutics show neurological applications, including Alzheimer's disease," said Miller, "Along with broader capabilities for developing assays - superior to traditional methods."
CPRI was founded in 1993, and remains a recognized provider of standard, unique and custom peptides for use in medical research, biology and biochemistry, continually maintaining a reputation for reliable and quality products in the peptide research field.
"This will provide Echelon an expanded offering of research reagents to our pharmaceutical and diagnostic customers," said Miller, "As well as incorporate the peptide expertise into our own research and development."
CPRI will relocate operations to the Salt Lake City-based facility of EBI, and join corporate divisions that include Logan, UT-based Frontier Scientific, Inc. and Newark, DE-based Frontier Scientific Services, Inc.
CPRI products will continue to be offered via the CPRI website, additionally via the EBI website and be offered in the near future through Frontier Scientific Services, Inc.
"We are please to have completed the acquisition of California Peptide," said Miller, "This acquisition allows Echelon to marry its strength, credibility and biochemical research expertise with the service and product offerings of CPRI."
About Echelon Biosciences, Inc.Established in 1997, Echelon Biosciences, Inc. (EBI) aims to further the science of lipid-cell signaling and critical metabolic enzymes through the development of biochemicals, assays and reagents that aid research in the fields of cancer, inflammation, neurobiology and metabolism. In 2007, EBI was acquired by Frontier Scientific, Inc., a recognized provider of boronic acids and porphyrin compounds for application development, and pharmaceutical and industrial research. Frontier Scientific Services, Inc. provides solutions for sample management and other common issues when conducting research -- sample library curation, standardization and re-formatting, compound procurement, storage and distribution, LC/GC-MS analysis and in-sourced staffing. California Peptide Research, Inc. (now) represents the fourth corporate division, whose peptide-based products are used in medical research, biology and biochemistry.
September 8, 2011 -- Press Release
For Immediate Release
ASDI Inc. assets acquired by Frontier Scientific Services Inc.
September 8th, 2011
Effective September 1st, 2011, Frontier Scientific Services, Inc. (FSSI) has acquired the assets of ASDI.
ASDI has been a recognized leader in providing chemical services to pharmaceutical, industrial, and academic clients. These valuable services now provided by FSSI include:
“We are pleased to have completed the acquisition of the assets of ASDI Inc.” said W. Tim Miller, President and CEO of Frontier Scientific. “This will allow the Frontier portfolio of companies to broaden our scope and expand our product and service offerings to our pharmaceutical, government and university customer base. The chemical procurement, library management, and analytical services of ASDI will complement our existing chemical building block and molecular biology product offerings.”
FSSI is private and will be managed as an independent portfolio company of Frontier Scientific Inc.
This transaction allows Frontier Scientific to marry its strength, credibility, and financial stability with the services and product offerings of ASDI. The ASDI name will be transitioned out over the next few months with seamless operations to customers. The entire ASDI catalog will still be available, contact information will remain the same, and the company will stay in the same location with the same address. The legacy of quick and responsive service will be improved with ongoing investments.
About Frontier Scientific Inc. (FSI)
This acquisition bolsters the late 2007 FSI acquisition of Echelon Biosciences Inc. (EBI), a Utah-based life science company. FSI’s investment in EBI opened the doors for expanded research with the aim to further the science of lipid cell signaling and critical metabolic enzymes, providing new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease. Since 1997, EBI has strengthened its commitment to developing novel assays and reagents for lipid research and beyond. (www.echelon-inc.com)
Although a common management team will guide the portfolio companies of Frontier Scientific Services, Frontier Scientific, and Echelon Biosciences, the companies will be run independently yet will offer common products and services where appropriate to best serve its customers.
W. Tim Miller, President and CEO
Kabana Perkins, General Manager
Frontier Scientific Services, Inc.